ClinicalTrials.gg
CompletedNCT03633617Updated Jun 28, 2023Results posted

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

A Phase 3 interventional study of Dupilumab and Placebo in Eosinophilic Esophagitis, sponsored by Regeneron Pharmaceuticals. Completed at 95 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-28.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
321
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing dupilumab in Eosinophilic Esophagitis — 4 open to participants now, 7 under way, 1 of them phase 3. dupilumab · Eosinophilic Esophagitis.

Enrollment
Largest of 11
321 · median 47
Started
2018
the only one that year
Phase 3
3 of 11
1 open now
Registered
2nd of 11
by date
Lead sponsor
5 of 11
Regeneron Pharmaceuticals

Among the 11 studies testing dupilumab in Eosinophilic Esophagitis, this one has the largest enrollment, is the only one that started in 2018, is one of 3 in phase 3, and was the 2nd registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

4 of the 11 studies testing dupilumab in Eosinophilic Esophagitis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing dupilumab in Eosinophilic Esophagitis, or all of them as a file.
02

Study summary

The primary objectives of the study by study part are:

Part A:

To determine the treatment effect of dupilumab compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures and to inform/confirm the final sample size determination for Part B.

Part B:

To demonstrate the efficacy of dupilumab treatment compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures.

Part C:

To assess the safety and efficacy of dupilumab treatment in adult and adolescent patients with EoE after up to 52 weeks of treatment as assessed by histological and clinical measures.

The secondary objectives of the study are:

  • To evaluate the safety, tolerability, and immunogenicity of dupilumab treatment for up to 52 weeks in adult and adolescent patients with EoE
  • To explore the relationship between dupilumab concentration and responses in adult and adolescent patients with EoE, using descriptive analyses
  • To evaluate the effects of dupilumab on transcriptomic signatures associated with EoE and type 2 inflammation
  • To demonstrate the efficacy of dupilumab treatment compared to placebo after 24 weeks and 52 weeks of treatment in adult and adolescent patients with EoE who have previously received swallowed topical corticosteroids
03

Conditions studied

  • Eosinophilic Esophagitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria (Parts A \& B):

  • A documented diagnosis of EoE by endoscopic
  • Baseline endoscopic biopsies with a demonstration on central reading of intraepithelial eosinophilic infiltration
  • History (by patient report) of an average of at least 2 episodes of dysphagia (with intake of solids) per week in the 4 weeks prior to screening

Key Exclusion Criteria (Parts A \& B):

  • Body weight ≤40 kg
  • Prior participation in a dupilumab clinical trial, or past or current treatment with dupilumab
  • Initiation or change of a food-elimination diet regimen or re-introduction of a previously eliminated food group in the 6 weeks prior to screening.
  • Other causes of esophageal eosinophilia or the following conditions: hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
  • Active Helicobacter pylori infection
  • History of achalasia, Crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery
  • Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to10 mm upper endoscope or any critical esophageal stricture that requires dilation at screening
  • History of bleeding disorders or esophageal varices
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study

Key Exclusion Criteria (Part C):

  • Participants who, during Part A or Part B, developed a serious adverse event (SAE) and/or adverse event (AE) deemed related to study drug, which in the opinion of the investigator could indicate that continued treatment with study drug may present an unreasonable risk for the participant
  • Participants who became pregnant during Part A or Part B
  • Participants who are prematurely discontinued from study drug due to an AE (patients who are prematurely discontinued from study drug due to lack of efficacy are eligible to enter Part C)
  • Patients who did not undergo endoscopy with biopsies prior to receiving rescue treatment

Note: Other inclusion/ exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
321 participants (actual)

Study arms

  • Experimental
    Part A: Dupilumab or Placebo

    Part A consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.

    Drug: Dupilumab · Drug: Placebo

  • Experimental
    Part B: Dupilumab or Placebo

    Part B consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.

    Drug: Dupilumab · Drug: Placebo

  • Experimental
    Part C: Dupilumab

    Part C is a 28-week extended active treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.

    Drug: Dupilumab

Interventions

  • Solution for injection administered subcutaneously

    Also known as: DUPIXENT, REGN668, SAR231893

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 24

    Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

    Time frame: At week 24

  2. Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 24

    The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.

    Time frame: Baseline and week 24

Secondary outcomes

  1. Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 24

    Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). A greater esophageal intraepithelial eosinophil count from baseline indicates worsening disease.

    Time frame: Baseline and week 24

  2. Percent Change From Baseline in DSQ Total Score at Week 24

    The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.

    Time frame: Baseline and week 24

  3. Absolute Change From Baseline in Eosinophilic Esophagitis Histology Scoring System (EoEHSS) Mean Grade Score at Week 24

    Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.

    Time frame: Baseline and week 24

  4. Absolute Change From Baseline in EoEHSS Mean Stage Score at Week 24

    Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.

    Time frame: Baseline and week 24

  5. Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 24

    EoE esophageal characteristics analyzed based on the EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.

    Time frame: Baseline and week 24

  6. Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 24

    Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

    Time frame: At week 24

  7. Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 24

    NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).

    Time frame: Baseline and week 24

  8. NES for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 24

    NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).

    Time frame: Baseline and week 24

  9. Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 24

    Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

    Time frame: At week 24

  10. Absolute Change From Baseline in Health-related Quality of Life (QoL) Average Score as Measured by EoE Impact Questionnaire (EoE-IQ) at Week 24

    The EoE-IQ measures impact of EoE on emotional, social, work \& school, \& sleep aspects. Participants were asked to respond to 11 questions based on experience living with EoE during past 7 days. Response to each item is on a 5-point scale (1=Not at all \[impacted\] 2=A little, 3=Somewhat, 4=Quite a bit, 5=Extremely \[impacted\]). The average score is the sum of non-missing responses divided by the number of items with non-missing responses. The average score can range from 1 to 5; a higher score is indicative of a more negative impact.

    Time frame: Baseline and week 24

  11. Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE Symptom Questionnaire (EoE-SQ) at Week 24

    The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the severity of each symptom based on the worst experience in the past 7 days is on a scale of 0 to 10 (higher is worse). The EoE-SQ severity score is calculated as the sum of the severity scores from questions 1 to 3 (chest pain, stomach pain, burning feeling in chest), which could range from 0 to 30; a higher score is indicative of more severe symptoms.

    Time frame: Baseline and week 24

  12. Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 24

    The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the frequency of each symptom is on a 5-point scale (1 = 'Never', 2 = 'One day', 3 = ' 2-6 days', 4 = 'Once a day', 5 = 'More than once a day'). The EoE-SQ frequency score is calculated as the sum of the frequency scores from the 5 items which could range from 5 to 25; a higher score is indicative of higher frequency of symptoms.

    Time frame: Baseline and week 24

  13. Percentage of Participants Who Received Rescue Treatment During the Placebo-controlled, Double-blind Treatment Period at Week 24

    Time frame: At week 24

  14. Absolute Change From Baseline in Esophageal Distensibility Plateau Measured by Functional Lumen Imaging, if Collected, at Week 24

    Time frame: At week 24

  15. Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 52

    Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

    Time frame: At week 52

  16. Absolute Change in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 52

    The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.

    Time frame: Baseline (of previous study part) and week 52

  17. Percent Change in DSQ Total Score at Week 52

    The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.

    Time frame: Baseline (of previous study part) and week 52

  18. Absolute Change in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52

    EoE esophageal characteristics analyzed based on the EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.

    Time frame: Baseline (of previous study part) and week 52

  19. Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 52

    Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). A greater esophageal intraepithelial eosinophil count from baseline indicates worsening disease.

    Time frame: Baseline (of previous study part) and week 52

  20. Absolute Change in EoE Histology Scoring System (EoEHSS) Mean Grade Score at Week 52

    Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.

    Time frame: Baseline (of previous study part) and week 52

  21. Absolute Change in EoEHSS Mean Stage Score at Week 52

    Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.

    Time frame: Baseline (of previous study part) and week 52

  22. Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 52

    Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

    Time frame: At week 52

  23. Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 52

    Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

    Time frame: At week 52

  24. Absolute Change in Health-related QOL as Measured by EoE-IQ at Week 52

    The EoE-IQ measures impact of EoE on emotional, social, work \& school, \& sleep aspects. Participants were asked to respond to 11 questions based on experience living with EoE during past 7 days. Response to each item is on a 5-point scale (1=Not at all \[impacted\] 2=A little, 3=Somewhat, 4=Quite a bit, 5=Extremely \[impacted\]). The average score is the sum of non-missing responses divided by the number of items with non-missing responses. The average score can range from 1 to 5; a higher score is indicative of a more negative impact.

    Time frame: Baseline (of previous study part) and week 52

  25. Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52

    The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the severity of each symptom based on the worst experience in the past 7 days is on a scale of 0 to 10 (higher is worse). The EoE-SQ severity score is calculated as the sum of the severity scores from questions 1 to 3 (chest pain, stomach pain, burning feeling in chest), which could range from 0 to 30; a higher score is indicative of more severe symptoms.

    Time frame: Baseline (of previous study part) and week 52

  26. Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52

    The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the frequency of each symptom is on a 5-point scale (1 = 'Never', 2 = 'One day', 3 = ' 2-6 days', 4 = 'Once a day', 5 = 'More than once a day'). The EoE-SQ frequency score is calculated as the sum of the frequency scores from the 5 items which could range from 5 to 25; a higher score is indicative of higher frequency of symptoms.

    Time frame: Baseline (of previous study part) and week 52

  27. Percentage of Participants Who Received Rescue Medication During the 28-week Extended Active Treatment Period

    Time frame: Baseline (of Part C) to week 28

  28. NES for the Relative Change From Baseline in EoE Diagnostic Panel (EDP) at Week 52

    NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).

    Time frame: Baseline (of previous study part) and week 52

  29. NES for the Relative Change in the Type 2 Inflammation Signature (T2INF) at Week 52

    NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).

    Time frame: Baseline (of previous study part) and week 52

  30. Concentration of Functional Dupilumab in Serum at Week 52

    Time frame: Baseline (of Part C) up to week 52

  31. Incidence of Treatment-emergent Anti-drug Antibody (ADA) Response

    Number of treatment-emergent ADA responses to dupilumab reported.

    Time frame: Baseline (of previous study part) up to week 52

07

Results

Posted Dec 28, 2022

Participant flow

Part A
Participant flow — Part A
MilestonePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWPart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Started3942000000000
Completed3637000000000
Not completed35000000000
Withdrew: Week 24 not performed due to coronavirus disease-2019 (covid-19)13000000000
Withdrew: Unconfirmed early termination visit10000000000
Withdrew: Adverse event01000000000
Withdrew: Pregnancy10000000000
Withdrew: Withdrawal by subject01000000000
Part B
Participant flow — Part B
MilestonePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWPart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Started00798180000000
Completed00747975000000
Not completed00525000000
Withdrew: Adverse event00221000000
Withdrew: Withdrawal by subject00102000000
Withdrew: Lost to follow-up00001000000
Withdrew: Physician decision00001000000
Withdrew: Covid-19 restrictions00100000000
Withdrew: Subject randomized, but did not receive study drug; did not qualify for study00100000000
Part C (& Follow-up)
Participant flow — Part C (& Follow-up)
MilestonePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWPart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Started00000374037377974
Completed week 52 (end of treatment)00000323834367465
Completed00000303533366764
Not completed0000075411210
Withdrew: Adverse event00000101000
Withdrew: Pregnancy00000000010
Withdrew: Withdrawal by subject00000220116
Withdrew: Lost to follow-up00000331072
Withdrew: Physician decision00000001001
Withdrew: Covid-19 related00000100000
Withdrew: Protocol violation00000000031
Withdrew: Lack of efficacy00000001000

Outcome measures

PrimaryPercentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 24

Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

Time frame:
At week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 24
Percentage of ParticipantsPart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 245.1 (0.63 to 17.32)59.5 (43.28 to 74.37)6.3 (2.09 to 14.16)60.5 (49.01 to 71.19)58.8 (47.18 to 69.65)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in proportion: 55.3 · 95% CI 39.58 to 71.04Difference is dupilumab minus placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in proportion: 56.0 · 95% CI 43.44 to 68.54Difference is dupilumab minus placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in proportion: 53.5 · 95% CI 41.20 to 65.79Difference is dupilumab minus placebo
PrimaryAbsolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 24

The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Score on a Scale
Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 24
Score on a ScalePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 24-9.60 (-15.056 to -4.136)-21.92 (-26.870 to -16.967)-13.86 (-17.605 to -10.120)-14.37 (-18.018 to -10.723)-23.78 (-27.427 to -20.131)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · ANCOVA · p = 0.0004 · Ls mean difference: -12.32 · 95% CI -19.107 to -5.537Dupilumab group vs. Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · ANCOVA · p = 0.8393 · Ls mean difference: -0.51 · 95% CI -5.423 to 4.406Dupilumab group vs. Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · ANCOVA · p = <0.0001 · Ls mean difference: -9.92 · 95% CI -14.811 to -5.022Dupilumab group vs. Placebo
SecondaryPercent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 24

Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). A greater esophageal intraepithelial eosinophil count from baseline indicates worsening disease.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Percentage of Change
Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 24
Percentage of ChangePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 24-2.98 (-17.886 to 11.921)-71.24 (-84.863 to -57.613)8.38 (-11.677 to 28.433)-70.84 (-87.095 to -54.585)-80.24 (-96.589 to -63.895)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · ANCOVA · p = <0.0001 · Ls mean difference: -68.26 · 95% CI -86.896 to -49.615Dupilumab 300 mg QW vs Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · ANCOVA · p = <0.0001 · Ls mean difference: -79.22 · 95% CI -103.098 to -55.338Dupilumab 300 mg Q2W vs Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · ANCOVA · p = <0.0001 · Ls mean difference: -88.62 · 95% CI -112.194 to -65.046Dupilumab 300 mg QW vs Placebo
SecondaryPercent Change From Baseline in DSQ Total Score at Week 24

The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Percentage of Change
Percent Change From Baseline in DSQ Total Score at Week 24
Percentage of ChangePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Percent Change From Baseline in DSQ Total Score at Week 24-31.68 (-47.545 to -15.818)-69.17 (-83.578 to -54.752)-41.43 (-51.749 to -31.116)-45.78 (-55.658 to -35.904)-64.32 (-74.267 to 54.382)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · ANCOVA · p = 0.0002 · Ls mean difference: -37.48 · 95% CI -57.222 to -17.745Dupilumab 300 mg QW vs Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · ANCOVA · p = 0.5243 · Ls mean difference: -4.35 · 95% CI -17.734 to 9.038Dupilumab 300 mg Q2W vs Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · ANCOVA · p = 0.0008 · Ls mean difference: -22.89 · 95% CI -36.272 to -9.513Dupilumab 300 mg QW vs Placebo
SecondaryAbsolute Change From Baseline in Eosinophilic Esophagitis Histology Scoring System (EoEHSS) Mean Grade Score at Week 24

Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Score on a Scale
Absolute Change From Baseline in Eosinophilic Esophagitis Histology Scoring System (EoEHSS) Mean Grade Score at Week 24
Score on a ScalePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Absolute Change From Baseline in Eosinophilic Esophagitis Histology Scoring System (EoEHSS) Mean Grade Score at Week 24-0.001 (-0.1166 to 0.1139)-0.761 (-0.8732 to -0.6484)-0.148 (-0.2379 to -0.0584)-0.814 (-0.8958 to -0.7317)-0.830 (-0.9136 to -0.7463)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · ANCOVA · p = <0.0001 · Ls mean difference: -0.759 · 95% CI -0.9061 to -0.6127Dupilumab 300 mg QW vs Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · ANCOVA · p = <0.0001 · Ls mean difference: -0.666 · 95% CI -0.7773 to -0.5538Dupilumab 300 mg Q2W vs Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · ANCOVA · p = <0.0001 · Ls mean difference: -0.682 · 95% CI -0.7929 to -0.5707Dupilumab 300 mg QW vs Placebo
SecondaryAbsolute Change From Baseline in EoEHSS Mean Stage Score at Week 24

Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Score on a Scale
Absolute Change From Baseline in EoEHSS Mean Stage Score at Week 24
Score on a ScalePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Absolute Change From Baseline in EoEHSS Mean Stage Score at Week 24-0.012 (-0.1243 to 0.0995)-0.753 (-0.8627 to -0.6441)-0.132 (-0.2179 to -0.0464)-0.793 (-0.8713 to -0.7144)-0.804 (-0.8839 to -0.7237)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · ANCOVA · p = <0.0001 · Ls mean difference: -0.741 · 95% CI -0.8842 to -0.5978Dupilumab 300 mg QW vs Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · ANCOVA · p = <0.0001 · Ls mean difference: -0.661 · 95% CI -0.7674 to -0.5540Dupilumab 300 mg Q2W vs Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · ANCOVA · p = <0.0001 · Ls mean difference: -0.672 · 95% CI -0.7778 to -0.5655Dupilumab 300 mg QW vs Placebo
SecondaryAbsolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 24

EoE esophageal characteristics analyzed based on the EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Score on a Scale
Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 24
Score on a ScalePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 24-0.3 (-1.11 to 0.50)-3.2 (-3.98 to -2.38)-0.6 (-1.37 to 0.12)-4.6 (-5.24 to -3.89)-4.5 (-5.17 to -3.77)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · ANCOVA · p = <0.0001 · Ls mean difference: -2.9 · 95% CI -3.91 to -1.84Dupilumab 300 mg QW vs Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · ANCOVA · p = <0.0001 · Ls mean difference: -3.9 · 95% CI -4.86 to -3.02Dupilumab 300 mg Q2W vs Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · ANCOVA · p = <0.0001 · Ls mean difference: -3.8 · 95% CI -4.77 to -2.93Dupilumab 300 mg QW vs Placebo
SecondaryPercentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 24

Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

Time frame:
At week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 24
Percentage of ParticipantsPart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 247.7 (1.62 to 20.87)64.3 (48.03 to 78.45)7.6 (2.84 to 15.80)79.0 (68.54 to 87.27)82.5 (72.38 to 90.09)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in proportion: 57.5 · 95% CI 41.69 to 73.33Difference is Dupilumab minus Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in proportion: 72.4 · 95% CI 61.05 to 83.70Difference is Dupilumab minus Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in proportion: 74.9 · 95% CI 64.25 to 85.50Difference is Dupilumab minus Placebo
SecondaryNormalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 24

NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).

Time frame:
Baseline and week 24
Reported as:
Number · Score on a Scale
Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 24
Score on a ScalePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 24-0.160-2.660-0.730-2.675-2.665
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · Wilcoxon rank-sum test · p = <0.0001 · Hodges-lehmann estimator: -2.250 · 95% CI -2.7200 to -1.7300Median Difference is Dupilumab minus Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · Wilcoxon rank-sum test · p = <0.0001 · Hodges-lehmann estimator: -1.840 · 95% CI -2.4200 to -1.1100Median Difference is Dupilumab minus Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · Wilcoxon rank-sum test · p = <0.0001 · Hodges-lehmann estimator: -1.850 · 95% CI -2.4400 to -1.1500Median Difference is Dupilumab minus Placebo
SecondaryNES for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 24

NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).

Time frame:
Baseline and week 24
Reported as:
Number · Score on a Scale
NES for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 24
Score on a ScalePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
NES for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 24-0.320-1.970-0.640-1.950-1.930
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · Wilcoxon rank-sum test · p = <0.0001 · Hodges-lehmann estimator: -1.590 · 95% CI -1.7400 to -1.2700Median Difference is Dupilumab minus Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · Wilcoxon rank-sum test · p = <0.0001 · Hodges-lehmann estimator: -1.255 · 95% CI -1.7300 to -1.0500Median Difference is Dupilumab minus Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · Wilcoxon rank-sum test · p = <0.0001 · Hodges-lehmann estimator: -1.275 · 95% CI -1.8200 to -1.0700Median Difference is Dupilumab minus Placebo
SecondaryPercentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 24

Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

Time frame:
At week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 24
Percentage of ParticipantsPart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 240.0 (0.00 to 9.03)21.4 (10.30 to 36.81)1.3 (0.03 to 6.85)27.2 (17.87 to 38.19)28.8 (19.18 to 39.95)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · Cochran-Mantel-Haenszel · p = 0.0017 · Difference in proportion: 21.9 · 95% CI 9.42 to 34.38Difference is Dupilumab minus Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in proportion: 27.6 · 95% CI 17.20 to 38.09Difference is Dupilumab minus Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in proportion: 28.9 · 95% CI 18.36 to 39.46Difference is Dupilumab minus Placebo
SecondaryAbsolute Change From Baseline in Health-related Quality of Life (QoL) Average Score as Measured by EoE Impact Questionnaire (EoE-IQ) at Week 24

The EoE-IQ measures impact of EoE on emotional, social, work \& school, \& sleep aspects. Participants were asked to respond to 11 questions based on experience living with EoE during past 7 days. Response to each item is on a 5-point scale (1=Not at all \[impacted\] 2=A little, 3=Somewhat, 4=Quite a bit, 5=Extremely \[impacted\]). The average score is the sum of non-missing responses divided by the number of items with non-missing responses. The average score can range from 1 to 5; a higher score is indicative of a more negative impact.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Score on a Scale
Absolute Change From Baseline in Health-related Quality of Life (QoL) Average Score as Measured by EoE Impact Questionnaire (EoE-IQ) at Week 24
Score on a ScalePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Absolute Change From Baseline in Health-related Quality of Life (QoL) Average Score as Measured by EoE Impact Questionnaire (EoE-IQ) at Week 24-0.246 (-0.4659 to -0.0266)-0.614 (-0.8140 to -0.4149)-0.578 (-0.6977 to -0.4585)-0.593 (-0.7152 to -0.4706)-0.887 (-1.0050 to -0.7685)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · ANCOVA · p = 0.0077 · Ls mean difference: -0.368 · 95% CI -0.6388 to -0.0975Dupilumab group vs Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · ANCOVA · p = 0.8586 · Ls mean difference: -0.015 · 95% CI -0.1782 to 0.1485Dupilumab group vs. Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · ANCOVA · p = 0.0002 · Ls mean difference: -0.309 · 95% CI -0.4703 to -0.1471Dupilumab group vs. Placebo
SecondaryAbsolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE Symptom Questionnaire (EoE-SQ) at Week 24

The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the severity of each symptom based on the worst experience in the past 7 days is on a scale of 0 to 10 (higher is worse). The EoE-SQ severity score is calculated as the sum of the severity scores from questions 1 to 3 (chest pain, stomach pain, burning feeling in chest), which could range from 0 to 30; a higher score is indicative of more severe symptoms.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Score on a Scale
Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE Symptom Questionnaire (EoE-SQ) at Week 24
Score on a ScalePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE Symptom Questionnaire (EoE-SQ) at Week 24-3.9 (-5.46 to -2.31)-5.8 (-7.24 to -4.44)-4.0 (-5.16 to -2.80)-4.5 (-5.59 to -3.32)-5.4 (-6.60 to 4.27)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · ANCOVA · p = 0.0467 · Ls mean difference: -2.0 · 95% CI -3.87 to -0.03Dupilumab group vs. Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · ANCOVA · p = 0.5469 · Ls mean difference: -0.5 · 95% CI -2.03 to 1.08Dupilumab group vs. Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · ANCOVA · p = 0.0718 · Ls mean difference: -1.5 · 95% CI -3.0 to 0.13Dupilumab group vs. Placebo
SecondaryAbsolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 24

The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the frequency of each symptom is on a 5-point scale (1 = 'Never', 2 = 'One day', 3 = ' 2-6 days', 4 = 'Once a day', 5 = 'More than once a day'). The EoE-SQ frequency score is calculated as the sum of the frequency scores from the 5 items which could range from 5 to 25; a higher score is indicative of higher frequency of symptoms.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Score on a Scale
Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 24
Score on a ScalePart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 24-1.7 (-2.67 to -0.71)-3.4 (-4.29 to -2.53)-2.6 (-3.25 to -1.87)-3.0 (-3.69 to -2.36)-3.9 (-4.61 to -3.25)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · ANCOVA · p = 0.0051 · Ls mean difference: -1.7 · 95% CI -2.93 to -0.52Dupilumab group vs. Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · ANCOVA · p = 0.3152 · Ls mean difference: -0.5 · 95% CI -1.38 to 0.44Dupilumab group vs. Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · ANCOVA · p = 0.0037 · Ls mean difference: -1.4 · 95% CI -2.30 to 0.45Dupilumab group vs. Placebo
SecondaryPercentage of Participants Who Received Rescue Treatment During the Placebo-controlled, Double-blind Treatment Period at Week 24
Time frame:
At week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Received Rescue Treatment During the Placebo-controlled, Double-blind Treatment Period at Week 24
Percentage of ParticipantsPart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QW
Percentage of Participants Who Received Rescue Treatment During the Placebo-controlled, Double-blind Treatment Period at Week 2412.8 (4.30 to 27.43)0.0 (0.00 to 8.41)2.5 (0.31 to 8.85)1.2 (0.03 to 6.69)2.5 (0.30 to 8.74)
Statistical analysis
  • Part A: Placebo vs Part A: Dupilumab 300 mg SC QW · Cochran-Mantel-Haenszel · p = 0.0170 · Difference in proportion: -12.7 · 95% CI -23.21 to -2.26Difference is Dupilumab minus Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC Q2W · Cochran-Mantel-Haenszel · p = 0.5493 · Difference in proportion: -1.3 · 95% CI -5.51 to 2.93Difference is Dupilumab minus Placebo
  • Part B: Placebo vs Part B: Dupilumab 300 mg SC QW · Cochran-Mantel-Haenszel · p = 0.9887 · Difference in proportion: 0.0 · 95% CI -4.9 to 5.02Difference is Dupilumab minus Placebo
SecondaryAbsolute Change From Baseline in Esophageal Distensibility Plateau Measured by Functional Lumen Imaging, if Collected, at Week 24
Time frame:
At week 24

No measurements were reported for this outcome.

SecondaryPercentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 52

Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

Time frame:
At week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 52
Percentage of ParticipantsPart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 5260.055.971.967.674.084.6
SecondaryAbsolute Change in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 52

The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.

Time frame:
Baseline (of previous study part) and week 52
Reported as:
Mean · Score on a Scale
Absolute Change in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 52
Score on a ScalePart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Absolute Change in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 52-21.71 ± 17.143-23.44 ± 16.149-23.69 ± 13.737-27.25 ± 11.457-20.87 ± 16.387-30.26 ± 15.389
SecondaryPercent Change in DSQ Total Score at Week 52

The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.

Time frame:
Baseline (of previous study part) and week 52
Reported as:
Mean · Percentage of Change
Percent Change in DSQ Total Score at Week 52
Percentage of ChangePart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Percent Change in DSQ Total Score at Week 52-65.87 ± 49.705-75.93 ± 36.892-71.01 ± 37.256-78.13 ± 31.003-61.19 ± 44.447-80.74 ± 32.866
SecondaryAbsolute Change in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52

EoE esophageal characteristics analyzed based on the EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.

Time frame:
Baseline (of previous study part) and week 52
Reported as:
Median · Score on a Scale
Absolute Change in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52
Score on a ScalePart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Absolute Change in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52-3.9 ± 2.74-4.1 ± 3.37-4.3 ± 3.21-6.1 ± 3.60-5.2 ± 3.40-5.3 ± 2.85
SecondaryPercent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 52

Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). A greater esophageal intraepithelial eosinophil count from baseline indicates worsening disease.

Time frame:
Baseline (of previous study part) and week 52
Reported as:
Mean · Percentage of Change
Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 52
Percentage of ChangePart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 52-83.76 ± 24.996-88.59 ± 13.506-91.20 ± 13.037-84.21 ± 42.169-84.78 ± 40.973-95.85 ± 4.037
SecondaryAbsolute Change in EoE Histology Scoring System (EoEHSS) Mean Grade Score at Week 52

Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.

Time frame:
Baseline (of previous study part) and week 52
Reported as:
Mean · Score on a Scale
Absolute Change in EoE Histology Scoring System (EoEHSS) Mean Grade Score at Week 52
Score on a ScalePart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Absolute Change in EoE Histology Scoring System (EoEHSS) Mean Grade Score at Week 52-0.873 ± 0.5506-0.873 ± 0.3537-0.779 ± 0.4292-0.906 ± 0.3936-0.838 ± 0.4039-0.968 ± 0.4293
SecondaryAbsolute Change in EoEHSS Mean Stage Score at Week 52

Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.

Time frame:
Baseline (of previous study part) and week 52
Reported as:
Mean · Score on a Scale
Absolute Change in EoEHSS Mean Stage Score at Week 52
Score on a ScalePart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Absolute Change in EoEHSS Mean Stage Score at Week 52-0.874 ± 0.4630-0.891 ± 0.2770-0.710 ± 0.3783-0.871 ± 0.3510-0.809 ± 0.3434-0.932 ± 0.3730
SecondaryPercentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 52

Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

Time frame:
At week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 52
Percentage of ParticipantsPart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 5270.082.487.578.483.6100
SecondaryPercentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 52

Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

Time frame:
At week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 52
Percentage of ParticipantsPart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 5226.729.440.616.231.530.8
SecondaryAbsolute Change in Health-related QOL as Measured by EoE-IQ at Week 52

The EoE-IQ measures impact of EoE on emotional, social, work \& school, \& sleep aspects. Participants were asked to respond to 11 questions based on experience living with EoE during past 7 days. Response to each item is on a 5-point scale (1=Not at all \[impacted\] 2=A little, 3=Somewhat, 4=Quite a bit, 5=Extremely \[impacted\]). The average score is the sum of non-missing responses divided by the number of items with non-missing responses. The average score can range from 1 to 5; a higher score is indicative of a more negative impact.

Time frame:
Baseline (of previous study part) and week 52
Reported as:
Mean · Score on a Scale
Absolute Change in Health-related QOL as Measured by EoE-IQ at Week 52
Score on a ScalePart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Absolute Change in Health-related QOL as Measured by EoE-IQ at Week 52-0.954 ± 0.6690-0.911 ± 0.6344-1.021 ± 0.7169-0.858 ± 0.6360-0.773 ± 0.6217-0.935 ± 0.6883
SecondaryAbsolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52

The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the severity of each symptom based on the worst experience in the past 7 days is on a scale of 0 to 10 (higher is worse). The EoE-SQ severity score is calculated as the sum of the severity scores from questions 1 to 3 (chest pain, stomach pain, burning feeling in chest), which could range from 0 to 30; a higher score is indicative of more severe symptoms.

Time frame:
Baseline (of previous study part) and week 52
Reported as:
Mean · Score on a Scale
Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52
Score on a ScalePart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52-7.2 ± 6.46-5.9 ± 6.80-6.2 ± 6.42-5.9 ± 6.47-4.7 ± 5.99-6.4 ± 6.86
SecondaryAbsolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52

The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the frequency of each symptom is on a 5-point scale (1 = 'Never', 2 = 'One day', 3 = ' 2-6 days', 4 = 'Once a day', 5 = 'More than once a day'). The EoE-SQ frequency score is calculated as the sum of the frequency scores from the 5 items which could range from 5 to 25; a higher score is indicative of higher frequency of symptoms.

Time frame:
Baseline (of previous study part) and week 52
Reported as:
Mean · Score on a Scale
Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52
Score on a ScalePart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52-4.3 ± 3.78-3.2 ± 3.50-4.0 ± 3.54-3.8 ± 3.62-3.6 ± 3.45-4.7 ± 4.03
SecondaryPercentage of Participants Who Received Rescue Medication During the 28-week Extended Active Treatment Period
Time frame:
Baseline (of Part C) to week 28
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Received Rescue Medication During the 28-week Extended Active Treatment Period
Percentage of ParticipantsPart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Percentage of Participants Who Received Rescue Medication During the 28-week Extended Active Treatment Period8.102.72.701.4
SecondaryNES for the Relative Change From Baseline in EoE Diagnostic Panel (EDP) at Week 52

NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).

Time frame:
Baseline (of previous study part) and week 52
Reported as:
Median · Score on a Scale
NES for the Relative Change From Baseline in EoE Diagnostic Panel (EDP) at Week 52
Score on a ScalePart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
NES for the Relative Change From Baseline in EoE Diagnostic Panel (EDP) at Week 52-2.580 (-2.87 to -0.45)-2.670 (-2.83 to -1.09)-2.28 (-2.8 to -0.8)-2.62 (-2.9 to -2.1)-2.64 (-2.9 to 1.2)-2.69 (-2.9 to -0.6)
SecondaryNES for the Relative Change in the Type 2 Inflammation Signature (T2INF) at Week 52

NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).

Time frame:
Baseline (of previous study part) and week 52
Reported as:
Median · Score on a Scale
NES for the Relative Change in the Type 2 Inflammation Signature (T2INF) at Week 52
Score on a ScalePart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
NES for the Relative Change in the Type 2 Inflammation Signature (T2INF) at Week 52-1.940 (-2.11 to -0.42)-1.970 (-2.07 to -0.95)-1.76 (-2.1 to -1.0)-1.96 (-2.1 to -1.5)-1.95 (-2.1 to 0.3)-1.97 (-2.2 to -0.7)
SecondaryConcentration of Functional Dupilumab in Serum at Week 52
Time frame:
Baseline (of Part C) up to week 52
Reported as:
Mean · milligrams per liter (mg/L)
Concentration of Functional Dupilumab in Serum at Week 52
milligrams per liter (mg/L)Part A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Week 32101 ± 44.6205 ± 76.846.0 ± 33.1124 ± 56.774.0 ± 42.0195 ± 94.6
Week 52137 ± 81.6152 ± 70.258.6 ± 36.5151 ± 96.068.9 ± 45.7176 ± 120
SecondaryIncidence of Treatment-emergent Anti-drug Antibody (ADA) Response

Number of treatment-emergent ADA responses to dupilumab reported.

Time frame:
Baseline (of previous study part) up to week 52
Reported as:
Number · Events
Incidence of Treatment-emergent Anti-drug Antibody (ADA) Response
EventsPart A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWPart A/C: Placebo / Dupilumab 300 mg QWPart A/C: Dupilumab 300 mg QW / Dupilumab 300 mg QWPart B/C: Placebo / Dupilumab 300 mg Q2WPart B/C: Placebo / Dupilumab 300 mg QWPart B/C: Dupilumab 300 mg Q2W / Dupilumab 300 mg Q2WPart B/C: Dupilumab 300 mg QW / Dupilumab 300 mg QW
Incidence of Treatment-emergent Anti-drug Antibody (ADA) Response00021411050

Adverse events

Collected over From day of first dose up to 12 weeks after end of treatment visit (week 52). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Placebo0/39 (0%)2/39 (5.1%)28/39 (71.8%)
Part A: Dupilumab 300 mg QW0/42 (0%)2/42 (4.8%)26/42 (61.9%)
Part B: Placebo0/78 (0%)1/78 (1.3%)41/78 (52.6%)
Part B: Dupilumab 300 mg Q2W0/81 (0%)2/81 (2.5%)57/81 (70.4%)
Part B: Dupilumab 300 mg QW0/80 (0%)5/80 (6.3%)50/80 (62.5%)
Part C: Dupilumab 300 mg Q2W (Placebo in Part B)0/37 (0%)1/37 (2.7%)19/37 (51.4%)
Part C: Dupilumab 300 mg QW (Placebo in Part A or B)0/74 (0%)3/74 (4.1%)44/74 (59.5%)
Part C: Dupilumab 300 mg Q2W (Part B Regimen Continued)0/79 (0%)1/79 (1.3%)47/79 (59.5%)
Part C: Dupilumab 300 mg QW (Part A or B Regimen Continued)0/114 (0%)4/114 (3.5%)62/114 (54.4%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPart A: PlaceboPart A: Dupilumab 300 mg QWPart B: PlaceboPart B: Dupilumab 300 mg Q2WPart B: Dupilumab 300 mg QWPart C: Dupilumab 300 mg Q2W (Placebo in Part B)Part C: Dupilumab 300 mg QW (Placebo in Part A or B)Part C: Dupilumab 300 mg Q2W (Part B Regimen Continued)Part C: Dupilumab 300 mg QW (Part A or B Regimen Continued)
Open globe injuryInjury, poisoning and procedural complications0/390/420/780/810/801/370/740/790/114
Suicidal ideationPsychiatric disorders1/390/420/782/810/800/370/740/790/114
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/390/420/780/810/800/370/740/790/114
Abdominal painGastrointestinal disorders0/391/420/780/810/800/370/740/790/114
Uterine polypReproductive system and breast disorders0/391/420/780/810/800/370/740/790/114
VomitingGastrointestinal disorders0/390/420/780/810/800/371/740/790/114
Systemic inflammatory response syndromeGeneral disorders0/390/420/780/810/800/371/740/790/114
CellulitisInfections and infestations0/390/420/780/810/800/371/740/790/114
Mental status changesPsychiatric disorders0/390/421/780/810/800/370/740/790/114
Generalised anxiety disorderPsychiatric disorders0/390/420/780/810/800/370/741/790/114
Most frequent other events
Showing 10 of 33
Most frequent other events
EventPart A: PlaceboPart A: Dupilumab 300 mg QWPart B: PlaceboPart B: Dupilumab 300 mg Q2WPart B: Dupilumab 300 mg QWPart C: Dupilumab 300 mg Q2W (Placebo in Part B)Part C: Dupilumab 300 mg QW (Placebo in Part A or B)Part C: Dupilumab 300 mg Q2W (Part B Regimen Continued)Part C: Dupilumab 300 mg QW (Part A or B Regimen Continued)
Injection site erythemaGeneral disorders6/394/429/7818/818/802/376/746/7910/114
Injection site reactionGeneral disorders5/399/4216/7818/8116/803/3712/7414/7914/114
Injection site swellingGeneral disorders1/395/422/787/8110/804/370/742/794/114
Injection site painGeneral disorders3/395/424/7810/817/804/376/746/799/114
NasopharyngitisInfections and infestations4/395/423/784/812/802/377/742/795/114
HeadacheNervous system disorders4/392/429/785/817/802/374/744/795/114
Blood creatine phosphokinase increasedInvestigations2/390/421/781/813/804/373/742/792/114
Eosinophilic oesophagitisGastrointestinal disorders0/390/420/780/810/804/370/740/790/114
Dermatitis atopicSkin and subcutaneous tissue disorders4/390/421/780/810/800/371/741/792/114
RashSkin and subcutaneous tissue disorders4/390/420/784/813/801/370/742/797/114

Baseline characteristics

Part A Full analysis set (FAS) includes all randomized participants in Part A; Part B FAS includes all randomized participants in Part B. Participants who participated in Part A were not eligible to participate in Part B.

Age, Customized
Age, Customized(Participants)Part A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWTotal
≥ 12 to < 18 years old911———20
≥ 18 to < 40 years old2213———35
≥ 40 to < 65 years old818———26
≥ 65 years old00———0
Age, Customized
Age, Customized(Participants)Part A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWTotal
≥ 12 to < 18 years old——26272679
≥ 18 to < 40 years old——383538111
≥ 40 to < 65 years old——15181548
≥ 65 years old——0112
Sex: Female, Male
Sex: Female, Male(Participants)Part A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWTotal
Female1814———32
Male2128———49
Sex: Female, Male
Sex: Female, Male(Participants)Part A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWTotal
Female——21363087
Male——584550153
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWTotal
Hispanic or Latino14———5
Not Hispanic or Latino3838———76
Unknown or Not Reported00———0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWTotal
Hispanic or Latino——53513
Not Hispanic or Latino——747775226
Unknown or Not Reported——0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWTotal
White3741———78
Black or African American11———2
Asian00———0
Other10———1
Not reported00———0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: PlaceboPart A: Dupilumab 300 mg SC QWPart B: PlaceboPart B: Dupilumab 300 mg SC Q2WPart B: Dupilumab 300 mg SC QWTotal
White——727471217
Black or African American——3328
Asian——1135
Other——2237
Not reported——1113

8 further baseline measures are reported on the registry.

08

Study locations

95 sites
  • Regeneron Study Site
    Phoenix, Arizona 85016, United States
  • Regeneron Study Site
    Scottsdale, Arizona 85259, United States
  • Regeneron Study Site
    Little Rock, Arkansas 72202, United States
  • Regeneron Study Site
    La Jolla, California 92037, United States
  • Regeneron Study Site
    Los Angeles, California 90025, United States
  • Regeneron Study Site
    Mountain View, California 94305, United States
  • Regeneron Study Site
    Orange, California 92868, United States
  • Regeneron Study Site
    Rolling Hills Estates, California 90274, United States
  • Regeneron Study Site
    San Diego, California 92123, United States
  • Regeneron Study Site
    Aurora, Colorado 80045, United States
  • Regeneron Study Site
    Aurora, Colorado 80220, United States
  • Regeneron Study Site
    Colorado Springs, Colorado 80907, United States
  • Regeneron Study Site
    Lone Tree, Colorado 80124, United States
  • Regeneron Study Site
    Bristol, Connecticut 06010, United States
  • Regeneron Study Site
    Miami, Florida 33156, United States
  • Regeneron Study Site
    Saint Petersburg, Florida 33701, United States
  • Regeneron Study Site
    Boise, Idaho 83706, United States
  • Regeneron Study Site
    Idaho Falls, Idaho 83404, United States
  • Regeneron Study Site #1
    Chicago, Illinois 60611, United States
  • Regeneron Study Site #2
    Chicago, Illinois 60611, United States
  • Regeneron Study Site
    Park Ridge, Illinois 60068, United States
  • Regeneron Study Site
    Urbana, Illinois 61801, United States
  • Regeneron Study Site
    Indianapolis, Indiana 46202, United States
  • Regeneron Study Site
    Clive, Iowa 50325, United States
  • Regeneron Study Site
    Iowa City, Iowa 52242, United States
  • Regeneron Study Site
    Topeka, Kansas 66606, United States
  • Regeneron Study Site
    Hagerstown, Maryland 21742, United States
  • Regeneron Study Site
    Boston, Massachusetts 02111, United States
  • Regeneron Study Site
    Worcester, Massachusetts 01655, United States
  • Regeneron Study Site
    Ann Arbor, Michigan 48109, United States
  • Regeneron Study Site
    Chesterfield, Michigan 48047, United States
  • Regeneron Study Site
    Plymouth, Minnesota 55446, United States
  • Regeneron Study Site
    Rochester, Minnesota 55905, United States
  • Regeneron Study Site
    Lincoln, Nebraska 68505, United States
  • Regeneron Study Site
    Omaha, Nebraska 68130, United States
  • Regeneron Study Site
    Bronx, New York 10461, United States
  • Regeneron Study Site
    Great Neck, New York 11021, United States
  • Regeneron Study Site
    Great Neck, New York 11023, United States
  • Regeneron Study Site
    New York, New York 10016, United States
  • Regeneron Study Site
    New York, New York 10029, United States
  • Regeneron Study Site
    New York, New York 10032, United States
  • Regeneron Study Site
    Chapel Hill, North Carolina 27599, United States
  • Regeneron Study Site
    Cincinnati, Ohio 45229, United States
  • Regeneron Study Site
    Dayton, Ohio 45415, United States
  • Regeneron Study Site
    Dublin, Ohio 43016, United States
  • Regeneron Study Site
    Mentor, Ohio 44060, United States
  • Regeneron Study Site
    Hershey, Pennsylvania 17033, United States
  • Regeneron Study Site
    Philadelphia, Pennsylvania 19104, United States
  • Regeneron Study Site
    Charleston, South Carolina 29425, United States
  • Regeneron Study Site
    Greenville, South Carolina 29615, United States
  • Regeneron Study Site
    Johnson City, Tennessee 37604, United States
  • Regeneron Study Site
    Memphis, Tennessee 38103, United States
  • Regeneron Study Site
    Dallas, Texas 75207, United States
  • Regeneron Study Site
    Fort Worth, Texas 76104, United States
  • Regeneron Study Site
    Garland, Texas 75044, United States
  • Regeneron Study Site
    Houston, Texas 77030, United States
  • Regeneron Study Site
    San Antonio, Texas 78229, United States
  • Regeneron Study Site
    Salt Lake City, Utah 84132, United States
  • Regeneron Study Site
    Charlottesville, Virginia 22903, United States
  • Regeneron Study Site
    Roanoke, Virginia 24013, United States
  • Regeneron Study Site
    Seattle, Washington 98115, United States
  • Regeneron Study Site
    Milwaukee, Wisconsin 53226, United States
  • Regeneron Study Site
    Camperdown, New South Wales 2050, Australia
  • Regeneron Study Site
    Woolloongabba, Queensland 4102, Australia
  • Regeneron Study Site
    Elizabeth Vale, South Australia 5112, Australia
  • Regeneron Study Site
    Melbourne, Victoria 3052, Australia
  • Regeneron Study Site
    Bruges, 8310, Belgium
  • Regeneron Study Site
    Edegem, 2650, Belgium
  • Regeneron Study Site
    Leuven, 03000, Belgium
  • Regeneron Study Site
    London, Ontario N6A5W9, Canada
  • Regeneron Study Site
    Ottawa, Ontario K1G6S6, Canada
  • Regeneron Study Site
    Montreal, Quebec H3T1C5, Canada
  • Regeneron Study Site
    Hamilton, L8S 1G5, Canada
  • Regeneron Study Site
    Pessac, 33604 Cedex, France
  • Regeneron Study Site
    Toulouse, TSA 50032-31059, France
  • Regeneron Study Site
    Hannover, 30459, Germany
  • Regeneron Study Site
    Magdeburg, 39120, Germany
  • Regeneron Study Site
    Munich, 81675, Germany
  • Regeneron Study Site
    Genoa, 16132, Italy
  • Regeneron Study Site
    Milano, 20122, Italy
  • Regeneron Study Site
    Naples, 80100, Italy
  • Regeneron Study Site
    Pisa, 56124, Italy
  • Regeneron Study Site
    Rome, 00161, Italy
  • Regeneron Study Site
    Rome, 00165, Italy
  • Regeneron Study Site
    Rozzano, 20089, Italy
  • Regeneron Study Site
    Amsterdam, 1105 AZ, Netherlands
  • Regeneron Study Site
    Maastricht, 6229HX, Netherlands
  • Regeneron Study Site
    Nijmegen, 6525GA, Netherlands
  • Regeneron Study Site
    Tomelloso, Ciudad Real 13700, Spain
  • Regeneron Study Site
    Barcelona, 08036, Spain
  • Regeneron Study Site
    Madrid, 28006, Spain
  • Regeneron Study Site
    Stockholm, 141 86, Sweden
  • Regeneron Study Site
    Zurich, CH-8091, Switzerland
  • Regeneron Study Site
    London, Whitechapel E1 1BB, United Kingdom
  • Regeneron Study Site
    Barnsley, Yorkshire S752EP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Sep 2021, 35 months.

Results were first posted in Dec 2022, 1 year 3 months after primary completion.

Of 16 phase 3 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 37. This study's 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2018
First posted
Aug 16, 2018
StartActual
Sep 24, 2018
Primary completionActual
Sep 9, 2021
CompletionActual
Jun 7, 2022
Results first posted
Dec 28, 2022
Last update
Jun 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03633617
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Aug 16, 2018
Start date
Sep 24, 2018
Primary completion
Sep 9, 2021
Completion
Jun 7, 2022
Results posted
Dec 28, 2022
Last update
Jun 28, 2023

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion